V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
I
IRONAI Stock Diagnostic Report

Disc Medicine rallies 32% as investors await bitopertin trial results

Disc Medicine's stock price has surged 32% ahead of the top-line results for its rare disease treatment drug Vitofitin in Phase 3 trials.

View Source Article ↗
AI CATALYST SCORE65 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

IRON Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-21 06:40:51IRON45MidView Report →
2026-10-19 11:29:58IRON85S-ClassView Report →
2026-10-19 09:01:50IRON65MidView Report →
View Full History for IRON (Blueprint) →